CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
805.00
+9.00 (1.13%)
At close: Mar 6, 2026
Market Cap15.39B -15.0%
Revenue (ttm)n/a
Net Income-1.25B
EPS-63.94
Shares Out19.11M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume113,500
Average Volume284,660
Open793.00
Previous Close796.00
Day's Range783.00 - 811.00
52-Week Range730.00 - 1,558.00
Beta-1.20
RSI44.61
Earnings DateFeb 13, 2026

About CanBas

CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. It develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 14
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements